Brought to you by 
Egalet raises $14.3mm in Series B financing
30 Mar 2021
Executive Summary
Danish pain management firm Egalet Ltd. has raised $14.3mm in Series B financing. First-time investor CLS Capital joined returning shareholders Atlas Venture, Omega Funds, Sunstone Capital, and Index Ventures. The company is preparing to advance into Phase III studies its lead candidate EGP066, an extended-release form of morphine that incorporates its controlled-release and abuse-deterring Egalet technology.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Controlled Release
-
Drug Delivery
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Egalet raises $14.3mm in Series B financing
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice